MarketMoodz
Biogen Advances Tau Drug Diranersen to Phase 3 Despite Mixed Data
Biogen plans to move its tau‑targeting antisense drug Diranersen into a Phase 3 program after mid‑stage results that showed mixed efficacy, CNBC reports. The lowest dose produced signals of tau reduction and slowed cognitive decline while higher doses failed to show superior benefit, leaving investors with a high‑stakes clinical bet.
Key Takeaways
- Biogen will advance Diranersen to Phase 3 despite mid‑stage results that were mixed, per CNBC reporting.
- Diranersen is an antisense oligonucleotide designed to lower tau production; the lowest dose showed biomarker and cognitive signals while higher doses did not.
- Dr. Priya Singhal, Biogen’s head of development, said the data meet three Phase 3 prerequisites: tau reduction, cognitive benefit, and dose isolation.
- The decision follows Biogen’s troubled history in Alzheimer’s—Aduhelm’s approval controversy—and arrives while Leqembi (lecanemab) is on the market.
- Advancing to Phase 3 creates clear upside if successful but raises regulatory, pricing and reimbursement risks that could pressure BIIB shares.
People Involved
- Dr. Priya SinghalHead of Development, Biogen
Entities Involved
- Biogen (BIIB)Developer of Diranersen and sponsor of the Phase 3 program
- DiranersenExperimental tau‑targeting antisense oligonucleotide
- EisaiPartner on amyloid therapies and collaborator on Alzheimer's treatments (Leqembi)
- Eli Lilly (LLY)Competitor pursuing tau‑reduction programs
- Aduhelm (aducanumab)Biogen/Eisai amyloid drug that faced approval controversy
- Leqembi (lecanemab)Eisai/Biogen amyloid therapy currently on the market
MarketMoodz Analysis
For investors, Biogen’s move is a classic high‑risk, high‑reward play. Advancing Diranersen despite uneven Phase 2/3 data signals management’s conviction that the lowest dose’s biomarker and cognitive signals are reproducible and clinically meaningful. If Phase 3 confirms tau lowering and a robust cognitive benefit, BIIB would gain a unique asset in a crowded Alzheimer’s landscape and could command meaningful valuation upside. Conversely, the mixed dose‑response raises execution risk: regulators will scrutinize why higher doses failed to outperform, and payers will demand clear, replicated clinical benefit before agreeing to generous reimbursement.
Context matters. Biogen carries the baggage of Aduhelm’s controversial approval and marketplace pushback, which left payers cautious and regulators more skeptical. Leqembi’s FDA clearance established a partial regulatory path for disease‑modifying therapies but did not erase pricing and access hurdles. Tau‑targeting approaches like Diranersen represent a complementary strategy to amyloid reduction, but the field is competitive—Eli Lilly and others are advancing tau programs—so a successful Phase 3 would not only help Biogen but could catalyze broader investment into tau biology.
What to watch next: Biogen’s Phase 3 design (endpoints, sample size, biomarker plans), interim biomarker readouts, regulatory interactions (including any path for accelerated approval), and how the company plans to set dosing after the mixed Phase 2/3 dose response. Also monitor payer signaling and analyst models for BIIB (ticker BIIB); positive interim data would likely re‑rate the stock, while another ambiguous result would deepen skepticism and re‑ignite pricing debates. Note that reporting is based on CNBC and company statements; some claims could not be independently verified and should be confirmed against Biogen’s press releases and regulatory filings.
Source: Original Article